<DOC>
	<DOCNO>NCT01684813</DOCNO>
	<brief_summary>The purpose study determine , type 2 diabetic patient undergo treatment PCI stent , fail respond normal dos clopidogrel , load dose 60 mg prasugrel follow 10 mg daily superior standard dose 75 mg clopidogrel achieve great 50 % inhibition platelet aggregation 24-36 hour treatment .</brief_summary>
	<brief_title>VERifynow DIabetes Non-responsiveness : Study Switching From Clopidogrel Prasugrel</brief_title>
	<detailed_description>The VERDI study consist randomize , mono-center study compare treatment plan load dose prasugrel oppose standard dose type 2 diabetic patient , suffer acute coronary syndrome , revascularized invasive percutaneous strategy stent . The aim study determine , type 2 diabetic patient undergo treatment PCI stent , fail respond normal dos clopidogrel , load dose 60 mg prasugrel follow 10 mg daily superior standard dose 75 mg clopidogrel achieve great 50 % inhibition platelet aggregation 24-36 hour treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>1 . Type 2 diabetic patient acute coronary syndrome nonST segment elevation undergo percutaneous coronary intervention ( PCI ) coronary stent . 2 . Patients nonresponsive platelet antiaggregation test standard dose clopidogrel randomize . 3 . Participants must sign informed consent document . 1 . Age &lt; 18 year &gt; 80 year . 2 . Patients acute coronary syndrome ST segment elevation . 3 . Pregnancy previous study . 4 . The use oral anticoagulant last 10 day INR &gt; 1.5 plan use followup period ( 1 year ) . 5 . Antithrombotic treatment GP IIb/IIIa inhibitor . 6 . Contraindication use prasugrel and/or clopidogrel and/or aspirin : Antecedents pharmacologic allergy thienopyridine derivative aspirin . Antecedents clinically significant persistent thrombocytopenia neutropenia . 7 . Active bleeding significant increase risk hemorrhage severe hepatic insufficiency , peptic ulcer present , proliferative diabetic retinopathy , antecedent severe systemic bleeding , gastrointestinal bleeding , macrohematuria , intraocular hemorrhage , hemorrhagic stroke , intracranial bleeding ) , antecedent bleed diathesis coagulopathy . 8 . Patients previous TIA CVA . 9 . Patients weigh &lt; 60 Kg . 10 . Hemoglobin &lt; 10.5 g/dl , Hematocrit &lt; 30 % . 11 . Severe leave ventricular systolic dysfunction , EF &lt; 35 % . 12 . Renal insufficiency creatinine level &gt; 2 mg/dl . 13 . Previous inclusion patient another study . 14 . Treatment research ( medication device ) last 30 day prior . 15 . Medical , geographical , social factor would make participation study impractical , incapacity provide write informed consent understand complete meaning informed consent , refusal patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Diabetes mellitus .</keyword>
	<keyword>Acute coronary syndrome .</keyword>
	<keyword>Percutaneous coronary intervention .</keyword>
</DOC>